OMEICOS Therapeutics
PrivateLast Round
Grant
Jun 21, 2023
Total Funding Raised
$42.26M
Company Overview
OMEICOS Therapeutics is a biopharmaceutical company that develops first-in-class small molecule therapeutics for the prevention and treatment of cardiovascular, ophthalmic, and inflammatory diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
OMEICOS Therapeutics Comparables
Compare OMEICOS Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Khondrion | 86% | |
| Abliva AB (publ) | 80% | |
| Reneo Pharmaceuticals | 78% |
OMEICOS Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Jun 21, 2023 | ||||
| Series C | Nov 2, 2018 | ||||
| Series B Extension | Oct 4, 2017 | ||||
| Grant | Jun 7, 2017 | ||||
| Series B | Mar 1, 2017 | ||||
Series A | Apr 15, 2015 |
Key People
Founding team and executive leadership
OMEICOS Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Federal Ministry of Education and Research | Grant |
| Forbion | Series C |
| IBB Ventures | Series B Extension, Series B, Series A, Seed, Series C |
| Bundesministerium für Bildung und Forschung | Grant |
| Remiges Ventures | Series B, Series C, Series B Extension |
| Ascenion | Series B, Grant |
| Vesalius Biocapital Partners | Series B Extension, Series C, Series B, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Feb 25, 2026
Grew 80% QoQ from 5 to 9 employees.
- Jun 21, 2023
Received $3M from Bundesministerium für Bildung und Forschung.
OMEICOS Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about OMEICOS Therapeutics's valuation, stock price, and market status.
Is OMEICOS Therapeutics a public or private company?
OMEICOS Therapeutics is a private company.
What is the current stock price of OMEICOS Therapeutics?
OMEICOS Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is OMEICOS Therapeutics worth (valuation)?
Valuation information for OMEICOS Therapeutics is not publicly available.
Can I buy OMEICOS Therapeutics stock?
OMEICOS Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was OMEICOS Therapeutics's last funding round?
OMEICOS Therapeutics's most recent funding round was Grant on June 21, 2023.
Who are the main investors in OMEICOS Therapeutics?
Key investors in OMEICOS Therapeutics include Forbion, Remiges Ventures, Vesalius Biocapital Partners.
Will OMEICOS Therapeutics IPO soon?
No public IPO plans have been announced for OMEICOS Therapeutics.
How can I track OMEICOS Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor OMEICOS Therapeutics's secondary market activity and sign up for updates.